Agenus Inc. said Bristol Myers Squibb Company returned rights to the TIGITxCD96-targeting bispecific antibody AGEN1777, the second piece of unwelcome news in less than a month for its immuno-oncology programs.
In a Securities and Exchange Commission filing on 2 August, Agenus said BMS had informed it that it would return...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?